adrenoglomerulotropin: aldosterone stimulating hormone found in extracts of pineal gland; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 71028 |
| CHEMBL ID | 221811 |
| SCHEMBL ID | 356345 |
| MeSH ID | M0040049 |
| Synonym |
|---|
| adrenoglomerulotropin |
| EU-0066833 |
| 9h-pyrido(3,4-b)indole, 1,2,3,4-tetrahydro-6-methoxy-1-methyl- |
| 1-methyl-6-methoxy-1,2,3,4-tetrahydro-beta-carboline |
| 1h-pyrido(3,4-b)indole, 2,3,4,9-tetrahydro-6-methoxy-1-methyl- |
| 1-methyl-6-methoxy-1,2,3,4-tetrahydro-2-carboline |
| brn 0747865 |
| 6-methoxy-1-methyl-1,2,3,4-tetrahydro-beta-carboline |
| 1h-pyrido[3,4-b]indole, 2,3,4,9-tetrahydro-6-methoxy-1-methyl- |
| OPREA1_020374 |
| OPREA1_696504 |
| IFLAB1_001355 |
| IDI1_009222 |
| CHEMDIV1_000195 |
| NCGC00163367-01 |
| bdbm50194444 |
| 6-methoxy-1-methyl-2,3,4,9-tetrahydro-1h-pyrido[3,4-b]indole |
| CHEMBL221811 , |
| HMS587I19 |
| AKOS004116723 |
| 1210-56-6 |
| 5-23-12-00070 (beilstein handbook reference) |
| unii-u18p8j9o2i |
| u18p8j9o2i , |
| CCG-103193 |
| mmtc |
| 2,3,4,9-tetrahydro-6-methoxy-1-methyl-1h-pyrido(3,4-b)indole |
| 6-methoxy-1,2,3,4-tetrahydroharman |
| 6-methoxydihydroharmalan |
| adrenoglomerulotropin [mi] |
| 6-meo-thh |
| dihydro-6-methoxyharmalan |
| 6-methoxytetrahydroharman |
| SCHEMBL356345 |
| AKOS022506354 |
| 1-methyl-6-methoxy-1,2, 3,4-tetrahydro-2-carboline |
| mmthc |
| .beta.-carboline, 1,2,3,4-tetrahydro-6-methoxy-1-methyl- |
| 6-methoxy-1-methyl-1,2,3,4-tetrahydro-.beta.-carboline |
| 6-methoxy-1-methyl-2,3,4,9-tetrahydro-1h-beta-carboline # |
| 1-methyl-6-methoxy-1,2,3,4-tetrahydro-.beta.-carboline |
| J-004434 |
| DTXSID20871835 |
| Q4057960 |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Microtubule-associated protein tau | Homo sapiens (human) | Potency | 3.9811 | 0.1800 | 13.5574 | 39.8107 | AID1460 |
| aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 39.8107 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Cholinesterase | Homo sapiens (human) | IC50 (µMol) | 10.0000 | 0.0000 | 1.5599 | 10.0000 | AID276346 |
| Acetylcholinesterase | Homo sapiens (human) | IC50 (µMol) | 10.0000 | 0.0000 | 0.9332 | 10.0000 | AID276345 |
| Delta-type opioid receptor | Mus musculus (house mouse) | IC50 (µMol) | 10.0000 | 0.0001 | 0.7298 | 10.0000 | AID276346 |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | Ki | 0.4910 | 0.0003 | 0.7693 | 10.0000 | AID537763 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID276345 | Inhibition of AChE | 2006 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 16, Issue:22 | 6-Hydroxy- and 6-methoxy-beta-carbolines as acetyl- and butyrylcholinesterase inhibitors. |
| AID537763 | Displacement of [3H]LSD from human cloned 5HT2B receptor expressed in CHO cells by liquid scintillation counting | 2010 | Journal of medicinal chemistry, Nov-11, Volume: 53, Issue:21 | Development, validation, and use of quantitative structure-activity relationship models of 5-hydroxytryptamine (2B) receptor ligands to identify novel receptor binders and putative valvulopathic compounds among common drugs. |
| AID276346 | Inhibition of BChE | 2006 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 16, Issue:22 | 6-Hydroxy- and 6-methoxy-beta-carbolines as acetyl- and butyrylcholinesterase inhibitors. |
| AID1347086 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347083 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347082 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4 | A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
| AID1347154 | Primary screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 4 (44.44) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 1 (11.11) | 24.3611 |
| 2020's | 3 (33.33) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (22.69) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 10 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||